VOR insider sales include trades up to $31; holdings disclosed

Rhea-AI Filing Summary

Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.

Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		S		24,689	D	$30.2207(1)	1,179,753(2)	D
Common Stock	10/17/2025		S		1,028	D	$31	1,178,725(2)	D
Common Stock	10/20/2025		S		11,616	D	$30.0535(3)	1,167,109(2)	D
Common Stock	10/21/2025		S		200	D	$30.075	1,166,909(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Hoffman Reid

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

3. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Reid Hoffman	10/21/2025
	/s/ Frank Huang, Manager of Reprogrammed Interchange LLC	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vor Biopharma (VOR) report?

Director Reid Hoffman reported open‑market sales on 10/17/2025, 10/20/2025, and 10/21/2025, with weighted average prices and price ranges disclosed.

How many Vor Biopharma shares does the reporting person own after the trades?

The filing lists 1,166,909 shares beneficially owned following the reported transactions.

What were the share amounts and prices for each reported sale?

10/17/2025: 24,689 shares at $30.2207 (range $30.00–$30.88) and 1,028 shares at $31.00. 10/20/2025: 11,616 shares at $30.0535 (range $30.00–$30.27). 10/21/2025: 200 shares at $30.075.

Through what entity are the shares held?

The securities are held by Reprogrammed Interchange LLC.

What is the reporting person’s relationship to Vor Biopharma?

The reporting person is listed as a Director.

Does the filing include a beneficial ownership disclaimer?

Yes. Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.

Was the Form 4 filed by more than one reporting person?

Yes. The form indicates it was filed by more than one reporting person, with signatures from Reid Hoffman and Frank Huang (Manager of Reprogrammed Interchange LLC).